Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

22 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-19

Study Completion Date

2018-11-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if telmisartan is effective in slowing the progression of abdominal aortic aneurysms and reducing circulating concentrations of Abdominal Aortic Aneurysms (AAA) biomarkers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ACZ885 for the Treatment of Abdominal Aortic Aneurysm

NCT02007252

Abdominal Aortic Aneurysm (AAA)

TERMINATED PHASE2

The Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients

NCT01670903

Aneurysm Hypertension

UNKNOWN

Exercise Therapy to Treat Adults With Abdominal Aortic Aneurysms

NCT00349947

Aortic Aneurysm, Abdominal

COMPLETED PHASE1

Renal Function After Stentgraft Treatment Of Abdominal Aortic Aneurysm

NCT04754659

Aortic Aneurysm, Abdominal Renal Insufficiency Stent-Graft Thrombosis

RECRUITING NA

The Efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion

NCT02070653

Abdominal Aortic Aneurysm

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Currently, the only management options for AAA are surgical (open or endovascular) based on ongoing follow-up with imaging at regular intervals. Telmisartan is currently approved for use in the United States by the Food and Drug Administration for management of hypertension. If telmisartan is found to be effective in slowing the progression of abdominal aortic aneurysms, this would provide a new treatment option for patients with AAA disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Aortic Aneurysm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Telmisartan

One 40mg telmisartan pill given once daily for 24 months

Group Type ACTIVE_COMPARATOR

Telmisartan

Intervention Type DRUG

Placebo

One 40mg placebo pill given once daily for 24 months

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Telmisartan

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 50-85 years of age and able to provide written informed consent
* AAA measuring a maximum diameter of 3.5-4.9 cm on CTA or ultrasound
* Stable medication regime for the last six months
* No current indication for AAA repair according to the treating physician or expectation that this will be revised within the next year
* High likelihood of compliance with treatment over 24 months

Exclusion Criteria

* Renal impairment (i.e. creatinine \>1.5x upper limit of normal \[ULN\])
* Known significant renal stenosis (\>70%) of one or both renal arteries
* Chronic liver disease (i.e. cirrhosis or hepatitis) or abnormal liver function (i.e. ALT 1.5xULN)
* Electrolyte imbalance
* Active gout
* Current or planned usage of an AT1 blocker or ACE inhibitor
* Previous abdominal aortic surgery
* Currently pregnant or intend to become pregnant

Minimum Eligible Age

50 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No